Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume $0.15 0.00 (-1.84%) (As of 12:20 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Viracta Therapeutics Short Interest DataViracta Therapeutics (VIRX) has a short interest of 2.69 million shares, representing 9.71% of the float (the number of shares available for trading by the public). This marks a 144.55% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.9, indicating that it would take 1.9 days of the average trading volume of 492,406 shares to cover all short positions.Current Short Interest2,690,000 sharesPrevious Short Interest1,100,000 sharesChange Vs. Previous Month+144.55%Dollar Volume Sold Short$542,842.00Short Interest Ratio1.9 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares39,740,000 sharesFloat Size27,710,000 sharesShort Percent of Float9.71%Today's Trading Volume109,568 sharesAverage Trading Volume492,406 sharesToday's Volume Vs. Average22% Short Selling Viracta Therapeutics? Sign up to receive the latest short interest report for Viracta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVIRX Short Interest Over TimeVIRX Days to Cover Over TimeVIRX Percentage of Float Shorted Over Time Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Viracta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20242,690,000 shares $542,842.00 +144.6%9.7%1.9 $0.20 10/15/20241,100,000 shares $241,560.00 -17.3%4.0%1.7 $0.22 9/30/20241,330,000 shares $307,762.00 +1.5%4.8%2.1 $0.23 9/15/20241,310,000 shares $328,810.00 +4.0%4.7%2.1 $0.25 8/31/20241,260,000 shares $269,136.00 -50.4%4.6%2.1 $0.21 8/15/20242,540,000 shares $885,190.00 +178.5%9.2%4.8 $0.35 Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/2024912,000 shares $436,848.00 -6.4%3.3%8.5 $0.48 7/15/2024974,800 shares $517,618.80 +35.2%3.5%10.7 $0.53 6/30/2024721,000 shares $392,007.70 +1.7%2.6%7 $0.54 6/15/2024708,900 shares $477,656.82 +3.8%2.6%6.7 $0.67 5/31/2024682,700 shares $477,890.00 +2.1%2.5%6.3 $0.70 5/15/2024668,400 shares $561,456.00 -4.4%2.4%6.5 $0.84 4/30/2024699,400 shares $573,228.24 +1.9%2.5%6.3 $0.82 4/15/2024686,700 shares $535,626.00 +6.0%2.5%6.2 $0.78 3/31/2024648,000 shares $660,960.00 +2.2%2.4%6.8 $1.02 3/15/2024634,300 shares $631,762.80 -7.1%2.3%5.7 $1.00 2/29/2024683,000 shares $556,645.00 +0.6%2.5%5 $0.82 2/15/2024678,800 shares $433,753.20 +4.5%2.5%4.5 $0.64 1/31/2024649,900 shares $370,443.00 +0.4%2.4%4 $0.57 1/15/2024647,500 shares $384,226.50 -1.9%2.4%3.8 $0.59 12/31/2023660,300 shares $376,371.00 -14.9%2.5%3.8 $0.57 12/15/2023776,100 shares $361,973.04 +19.3%2.9%4.6 $0.47 11/30/2023650,700 shares $316,890.90 -8.2%2.4%4.9 $0.49 11/15/2023708,700 shares $425,503.48 +3.0%2.6%7.3 $0.60 10/31/2023688,200 shares $424,275.30 +12.0%2.6%7.5 $0.62 10/15/2023614,700 shares $436,437.00 -2.7%2.3%7.6 $0.71 9/30/2023632,000 shares $657,280.00 -4.3%2.4%7 $1.04 9/15/2023660,200 shares $838,454.00 -5.3%2.5%7.8 $1.27 8/31/2023697,200 shares $1.00 million -4.4%2.6%6.8 $1.44 8/15/2023729,100 shares $947,830.00 +5.2%2.7%4.5 $1.30 7/31/2023692,900 shares $1.07 million -3.9%2.6%2.8 $1.55 7/15/2023721,000 shares $1.05 million -1.0%2.7%2.9 $1.45 6/30/2023728,500 shares $1.03 million -7.8%2.8%3 $1.41 6/15/2023789,900 shares $1.26 million +14.0%3.0%3.3 $1.59 5/31/2023693,200 shares $921,956.00 +12.4%2.6%3.2 $1.33 5/15/2023616,700 shares $807,877.00 -2.2%2.3%3.4 $1.31 4/30/2023630,800 shares $813,732.00 +2.0%2.4%8.4 $1.29 4/15/2023618,300 shares $902,718.00 -2.5%2.3%9.6 $1.46 3/31/2023634,000 shares $1.01 million -19.5%2.4%8.4 $1.59 3/15/2023787,800 shares $1.33 million +51.7%3.0%8.7 $1.69Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. 2/28/2023519,200 shares $882,640.00 +3.9%2.0%4.9 $1.70 2/15/2023499,500 shares $994,005.00 +5.6%1.9%4.5 $1.99 1/31/2023473,000 shares $983,840.00 -2.5%1.8%3.8 $2.08 1/15/2023485,300 shares $1.10 million +3.2%1.8%3.9 $2.26 12/30/2022470,300 shares $686,638.00 -15.1%1.8%3.8 $1.46 12/15/2022553,600 shares $1.06 million -0.1%2.1%5.2 $1.92 11/30/2022553,900 shares $1.29 million +7.3%2.1%5.1 $2.32 11/15/2022516,200 shares $1.50 million +8.8%2.0%4.8 $2.90 10/31/2022474,600 shares $1.87 million -9.6%1.9%4.7 $3.93 10/15/2022525,100 shares $1.97 million -4.4%2.0%5.1 $3.75 9/30/2022549,000 shares $2.34 million +9.3%2.1%5 $4.27 9/15/2022502,100 shares $2.81 million -3.9%2.0%2.6 $5.59 8/31/2022522,300 shares $2.12 million +0.6%2.0%2.3 $4.05 8/15/2022519,100 shares $2.29 million -8.2%2.0%2.2 $4.42 7/31/2022565,400 shares $1.88 million -16.1%1.9%2.2 $3.32 7/15/2022673,800 shares $2.99 million -32.5%2.3%2.5 $4.44 6/30/2022998,500 shares $3.87 million -48.5%3.4%3.2 $3.88 6/15/20221,940,000 shares $4.85 million -3.0%6.5%6.1 $2.50 5/31/20222,000,000 shares $4.24 million +8.7%6.7%8.1 $2.12 5/15/20221,840,000 shares $3.44 million -7.1%6.2%7.3 $1.87 4/30/20221,980,000 shares $5.05 million +16.5%6.7%6.2 $2.55 4/15/20221,700,000 shares $6.90 million +20.6%5.7%5.2 $4.06 3/31/20221,410,000 shares $6.71 million +20.5%4.8%4.7 $4.76 3/15/20221,170,000 shares $2.61 million +13.6%3.9%4.2 $2.23 2/28/20221,030,000 shares $2.81 million +7.8%3.5%3.5 $2.73 2/15/2022955,900 shares $2.98 million +26.0%3.2%3 $3.12 1/31/2022758,800 shares $2.03 million +5.5%2.7%2.9 $2.68 1/15/2022719,100 shares $2.28 million -15.4%2.5%3.3 $3.17 12/31/2021849,800 shares $3.10 million -2.7%3.0%3.7 $3.65 12/15/2021873,100 shares $3.12 million +30.4%3.1%4 $3.57 11/30/2021669,400 shares $3.09 million -24.3%2.4%3.8 $4.61 11/15/2021884,500 shares $4.93 million -15.0%3.1%5.5 $5.57 10/29/20211,040,000 shares $6.12 million -7.1%3.5%6.6 $5.88 10/15/20211,120,000 shares $7.25 million -1.8%3.8%7.5 $6.47 9/30/20211,140,000 shares $9.14 million -5.0%3.8%8.5 $8.02 9/15/20211,200,000 shares $10.08 million -9.1%4.0%5.5 $8.40 8/31/20211,320,000 shares $12.17 million -15.9%4.4%4.9 $9.22 8/13/20211,570,000 shares $16.11 million No Change5.3%5.7 $10.26 VIRX Short Interest - Frequently Asked Questions What is Viracta Therapeutics' current short interest? Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 2,690,000 shares of VIRX short. 9.71% of Viracta Therapeutics' shares are currently sold short. Learn More on Viracta Therapeutics' current short interest. What is a good short interest ratio for Viracta Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VIRX shares currently have a short interest ratio of 2.0. Learn More on Viracta Therapeutics's short interest ratio. What is a good short interest percentage for Viracta Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.71% of Viracta Therapeutics' floating shares are currently sold short. Is Viracta Therapeutics' short interest increasing or decreasing? Viracta Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 2,690,000 shares, an increase of 144.5% from the previous total of 1,100,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Viracta Therapeutics' float size? Viracta Therapeutics currently has issued a total of 39,740,000 shares. Some of Viracta Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Viracta Therapeutics currently has a public float of 27,710,000 shares. How does Viracta Therapeutics' short interest compare to its competitors? 9.71% of Viracta Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Calidi Biotherapeutics, Inc. (7.72%), Tempest Therapeutics, Inc. (11.82%), Chemomab Therapeutics Ltd. (1.29%), Cocrystal Pharma, Inc. (0.03%), Acurx Pharmaceuticals, Inc. (3.43%), Pulmatrix, Inc. (0.19%), Exicure, Inc. (4.71%), MIRA Pharmaceuticals, Inc. (12.65%), Pieris Pharmaceuticals, Inc. (1.70%), Cyclo Therapeutics, Inc. (0.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Viracta Therapeutics stock? Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. VIRX shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viracta Therapeutics? A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further. How often is Viracta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies CLDI Short Squeeze TPST Short Squeeze CMMB Short Squeeze COCP Short Squeeze ACXP Short Squeeze PULM Short Squeeze XCUR Short Squeeze MIRA Short Squeeze PIRS Short Squeeze CYTH Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VIRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.